Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Evidence-Based Immunology and Infectious Disease, the fourth title in the news series from The American Journal of Managed Care, launches with an issue that features interviews with leading AIDS researchers, a discussion of the challenges of paying for breakthrough therapies for hepatitis C, and new information on causes and treatments for rheumatoid arthritis.
Leaders from the Centers for Medicare & Medicaid Services think private insurers have been too slow to adopt payment reforms, but they would be best served by adopting value-based payment systems in tandem with CMS today.